Plasma Phosphorylated Tau 217 to Identify Preclinical Alzheimer Disease

Can plasma phosphorylated tau 217 (p-tau217) reliably identify amyloid β (Aβ) status in cognitively unimpaired individuals for participant selection in preclinical Alzheimer disease (AD) trials or for potential future use in clinical practice?In this cohort study of 2916 cognitively unimpaired individuals, plasma p-tau217 demonstrated good accuracy in predicting Aβ positivity. However, achieving a positive predictive value above 90% required confirmatory testing with a cerebrospinal fluid or positron emission tomography test.Plasma p-tau217 is a useful stand-alone marker of Aβ status in cognitively unimpaired individuals when moderate accuracy suffices, but adding another test in a second step is needed to achieve a high accuracy in this population.

Corresponding Authors: Oskar Hansson, MD, PhD (oskar.hansson@med.lu.se), and Gemma Salvadó, PhD (gemma.salvado@med.lu.se); Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University; S:t Johannesgatan 8, 211 46 Malmö, Sweden.

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.